Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Corning (GLW) Beats Q2 Earnings Estimates on Strong Revenues

Corning's (GLW) second-quarter results benefited from the revenue upside driven by strength in the company's Optical Communications and Specialty Materials business lines.

AAPL : 153.46 (+0.47%)
GLW : 30.42 (-5.32%)
VZ : 44.40 (+0.95%)
PFE : 32.89 (-0.63%)
Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?

While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.

CELG : 137.75 (+0.96%)
NVO : 41.99 (-0.40%)
JNJ : 130.95 (-0.71%)
PFE : 32.89 (-0.63%)
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger

The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger

GOOGL : 965.31 (-0.38%)
ABT : 50.40 (-0.85%)
SLB : 66.99 (-0.03%)
ORCL : 51.17 (unch)
PFE : 32.89 (-0.63%)
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline

Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?

MRK : 61.80 (-0.90%)
LLY : 81.84 (-0.43%)
INCY : 137.19 (+2.72%)
PFE : 32.89 (-0.63%)
Pfizer Becomes #20 Most Shorted Dow Stock, Replacing Johnson & Johnson

The most recent short interest data has been released for the 07/14/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the...

PFE : 32.89 (-0.63%)
Top Analyst Reports for Oracle, Pfizer & Abbott

Top Analyst Reports for Oracle, Pfizer & Abbott

GOOGL : 965.31 (-0.38%)
ABT : 50.40 (-0.85%)
EBAY : 37.04 (+1.98%)
SLB : 66.99 (-0.03%)
ORCL : 51.17 (unch)
PFE : 32.89 (-0.63%)
Ophthalmic Drugs Market to Reach US$34.3 Billion by 2025: Players Entering Into Co-development Agreements to Enhance Product Portfolio

ALBANY, New York, July 25, 2017 /PRNewswire/ --

VRX.TO : 22.10 (-0.27%)
BAYRY : 130.5700 (+0.43%)
AERI : 54.70 (-2.23%)
SNPHF : 13.2500 (-0.69%)
AGN : 256.15 (+0.60%)
NVS : 84.85 (+0.77%)
REGN : 515.63 (+0.42%)
PFE : 32.89 (-0.63%)
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

LONDON, July 25, 2017 /PRNewswire/ --

GSK : 40.85 (-2.65%)
PFE : 32.89 (-0.63%)
NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials

NantKwest Inc. (Nasdaq:NK), a clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious...

NK : 7.15 (-1.79%)
PFE : 32.89 (-0.63%)
MKKGY : 37.5500 (-16.56%)
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.

ZTS : 62.06 (+1.27%)
CLVS : 87.43 (+1.70%)
PFE : 32.89 (-0.63%)
MKGAF : 110.5500 (-3.45%)
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

XLV : 80.11 (-0.34%)
VHT : 149.13 (-0.35%)
MRK : 61.80 (-0.90%)
IYH : 168.03 (-0.31%)
FHLC : 38.71 (-0.26%)
ABBV : 72.59 (+0.10%)
GILD : 74.19 (+0.61%)
AMGN : 175.89 (-2.76%)
PFE : 32.89 (-0.63%)
BMY : 55.98 (+0.05%)
Pfizer Inc (PFE) Approaches New Downside Target of $33.29

Shares of Pfizer Inc (NYSE:PFE) opened today below their pivot of $33.48 and have already reached the first level of support at $33.39. Should the shares continue to fall, the support pivots of $33.29...

PFE : 32.89 (-0.63%)
What to Expect from Anthem (ANTM) this Earnings Season?

Anthem's (ANTM) second-quarter earnings are likely to be supported by robust medical enrollment. However, rising level of SG&A expenses might put pressure on the bottom line.

HUM : 233.50 (-0.60%)
ANTM : 184.99 (-2.93%)
ALGN : 158.69 (+0.08%)
PFE : 32.89 (-0.63%)
Centene (CNC) to Report Q2 Earnings: What's in the Cards?

Centene's (CNC) second-quarter earnings are likely to be driven by Health Net buyout. However, surging level of SG&A expenses might put pressure on the bottom line.

HUM : 233.50 (-0.60%)
CNC : 83.39 (+0.65%)
ALGN : 158.69 (+0.08%)
PFE : 32.89 (-0.63%)
Universal Health (UHS) Q2 Earnings: What's in the Cards?

Universal Health's (UHS) second-quarter earnings are likely to be boosted by solid revenue growth. However, increasing cost of debt might hurt the bottom line.

HUM : 233.50 (-0.60%)
UHS : 112.88 (-8.15%)
ALGN : 158.69 (+0.08%)
PFE : 32.89 (-0.63%)
Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin(R)(1) (bevacizumab)

Pfizer Inc. (NYSE:PFE) today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin(R) (bevacizumab), met its primary...

PFE : 32.89 (-0.63%)
Featured Company News - Pfizer and Merck Announce EMA'S CHMP Positive Opinion for Avelumab

MAIN, GERMANY / ACCESSWIRE / July 24, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Pfizer Inc. (NYSE: PFE), following which we have published a...

MRK : 61.80 (-0.90%)
PFE : 32.89 (-0.63%)
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

XLV : 80.11 (-0.34%)
VHT : 149.13 (-0.35%)
MRK : 61.80 (-0.90%)
IYH : 168.03 (-0.31%)
FHLC : 38.71 (-0.26%)
ABBV : 72.59 (+0.10%)
GILD : 74.19 (+0.61%)
AMGN : 175.89 (-2.76%)
PFE : 32.89 (-0.63%)
BMY : 55.98 (+0.05%)
Merck's Biosimilar Insulin Gets Tentative FDA Approval

Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

MRK : 61.80 (-0.90%)
LLY : 81.84 (-0.43%)
PFE : 32.89 (-0.63%)
SNY : 48.02 (-0.10%)
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

NVO : 41.99 (-0.40%)
JNJ : 130.95 (-0.71%)
ABBV : 72.59 (+0.10%)
PFE : 32.89 (-0.63%)

Van Meerten Stock Picks

5 Great Growth Stocks
Each week Value Line publishes a list of growth stocks the for the past 10 years have had a 10% increase in Sales, Cash Flow, Earnings, Dividends and Book Value and are expected to continue that 10% growth for the next 5 years.
NVDA +1.91 , CGNX +0.27 , EDU +2.17 , LUV +0.70 , ZBRA -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Sep S&P 500 E-mini stock futures ( ESU17 +0.16%) this morning are trading slightly higher by +0.1% on support from this morning's +0.49% rally in the Euro Stoxx 50 index. Global stocks are getting a boost from... Read More

Chart of the Day

Chart of the Day

GasLog (GLOG) is the Barchart Chart of the Day.  The LNG carrier is a growth turnaround play with a Weighted Alpha of 39.73+, gained 32.02% in the last year and paid a 3.15% dividend.
Read More

Brugler Ag Report

Today's Commentary

Corn futures finished Wednesday trade with most contracts rebounding to finish 3 to 4 1/4 cents in the green. Analysts are expecting Thursday morning’s Export Sales report to show 200,000-500,000 MT of old crop sales, with 200,000-400,000 MT in...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.